Booster Therapeutics

Booster Therapeutics is pioneering a new class of drugs that activate the cell's natural quality control mechanisms to treat a range of complex conditions. Booster’s small-molecule therapies, discovered through the DGRADX™ platform, are designed to directly enhance the activity of the 20S proteasome to restore the body's ability to clear pathogenic proteins. The company is developing a multi-disease pipeline, initially focusing on neurodegenerative diseases associated with impaired proteasome function, such as Parkinson's disease and Alzheimer's disease. Booster is headquartered in Berlin, Germany.